Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Harvard-MIT Division of Health Sciences and Technology 65 Landsdowne Street, Cambridge, MA 02139, USA.
Trends Mol Med. 2010 May;16(5):203-9. doi: 10.1016/j.molmed.2010.02.005. Epub 2010 Mar 23.
Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical paradigm; however, recent trials have produced mixed results. Although MSC were originally considered to treat connective tissue defects, preclinical studies revealed potent immunomodulatory properties that prompted the use of MSC to treat numerous inflammatory conditions. Unfortunately, although clinical trials have met safety endpoints, efficacy has not been demonstrated. We believe the challenge to demonstrate efficacy can be attributed in part to an incomplete understanding of the fate of MSC following infusion. Here, we highlight the clinical status of MSC therapy and discuss the importance of cell-tracking techniques, which have advanced our understanding of the fate and function of systemically infused MSC and might improve clinical application.
间充质干细胞 (MSC) 治疗有望建立新的临床范例；然而，最近的试验产生了混合的结果。尽管 MSC 最初被认为可以治疗结缔组织缺陷，但临床前研究揭示了其强大的免疫调节特性，促使人们将 MSC 用于治疗多种炎症性疾病。不幸的是，尽管临床试验达到了安全性终点，但疗效尚未得到证实。我们认为，疗效难以得到证明的部分原因可以归因于对 MSC 输注后命运的不完全了解。在这里，我们重点介绍 MSC 治疗的临床现状，并讨论细胞示踪技术的重要性，该技术提高了我们对系统性输注 MSC 的命运和功能的理解，并可能改善临床应用。
